Two injections, two different jobs in the hip joint

"My consultant mentioned ChondroFiller or a hyaluronic acid injection — are they basically the same thing?" They are not. Although both are outpatient procedures delivered under imaging guidance into the hip joint, the biology each treatment triggers once inside the joint differs fundamentally.

Hyaluronic acid (HA) works lubricatively: injected into the hip, it restores the viscoelastic properties of synovial fluid that arthritis has degraded — reducing friction, cushioning bone surfaces, and calming inflammatory pain signals. It does not repair or replace tissue.

ChondroFiller injection works regeneratively: the collagen gel self-sets within the joint in approximately 3–5 minutes, forming a structural scaffold that the patient's own progenitor cells migrate into and begin converting into new cartilage matrix. It does not simply lubricate.

Which is appropriate depends on the structural diagnosis. Diffuse mild-to-moderate hip osteoarthritis and a focal full-thickness cartilage defect are different clinical problems, and these two injections are designed for each of them — not as competing options for the same patient, but as tools matched to different stages and patterns of joint damage.

How hyaluronic acid works inside the hip joint

In a healthy hip joint, synovial fluid owes its remarkable cushioning quality to naturally occurring hyaluronic acid — a long-chain molecule that gives the fluid its thick, gel-like viscosity. Osteoarthritis degrades these chains, thinning the fluid and leaving cartilage surfaces with far less protection. An injected HA supplement restores that viscoelastic quality: under load, the fluid thickens to absorb impact; during movement, it thins to reduce shear and friction between surfaces. Beyond this mechanical role, injected HA suppresses inflammatory mediators within the synovial lining and coats intra-articular nerve endings directly, producing an anti-nociceptive effect that can reduce pain signalling independently of the lubrication it provides. There is also evidence that HA injections prompt chondrocytes and synoviocytes to resume producing their own endogenous HA — a secondary biological benefit that may extend the symptomatic window beyond the injected material's residence time.

What HA does not do is equally important: it does not rebuild or replace cartilage tissue. The intervention is symptomatic and lubricative, not structural.

Molecular weight influences how well the injected product performs. Trials evaluating hip OA — including De Lucia (2019) and Mauro (2018) — suggest that a hybrid complex combining high molecular weight HA (1,100–1,400 kDa) with low molecular weight HA (80–100 kDa) produces better clinical outcomes than high molecular weight HA alone. This evidence base, supported by multiple RCTs and cohort studies including Qvistgaard et al. (2006) and Spitzer et al. (2010), applies to mild-to-moderate hip osteoarthritis; benefit varies by patient and disease stage. Symptom relief typically emerges four to six weeks after injection and may last up to six months, and repeated courses of one to three injections have been studied for patients who respond well initially.

How ChondroFiller injection works as a regenerative scaffold

The defining moment in ChondroFiller injection happens within the first few minutes after placement: the cell-free collagen gel, guided into the hip joint under real-time ultrasound, self-sets in situ within approximately three to five minutes. What forms is not a fluid supplement but a structural Type I collagen scaffold positioned directly over the damaged cartilage surface.

ChondroFiller is produced by Meidrix Biomedicals (Germany) and CE-marked as a Class III medical device — the highest European regulatory category for injectable implantable materials. It contains no living cells and no hyaluronic acid. The collagen matrix it creates acts as a chemotactic template: the patient's own progenitor cells and chondrocytes migrate into the scaffold and begin generating new cartilage tissue, a process described as matrix-induced chondrogenesis.

This is a regenerative pathway, not a lubricative one. ChondroFiller injection targets the structural defect — providing a physical scaffold to support biological repair — rather than restoring the fluid environment around it, which is HA's role.

Because the gel self-sets within the joint without requiring surgical preparation of the cartilage bed, ChondroFiller injection is an outpatient procedure carried out under local anaesthesia. No general anaesthetic, no theatre booking, and no arthroscopic debridement are involved; ultrasound tracking guides placement throughout and intravenous antibiotic cover is administered at the time of the procedure.

The Mazek (2021) prospective cohort (n=26) provides the most specific published hip outcome data for ChondroFiller: 17 of 21 evaluable patients achieved good or excellent MRI-verified cartilage healing scores at three-to-five-year follow-up. The current evidence base for the injectable format remains limited to smaller cohorts and awaits large-scale RCT validation.

Which hip patients suit each pathway

Patient selection is where these two pathways diverge most clearly in practice — and grading matters.

HA suits mild-to-moderate diffuse hip OA. The typical HA candidate has widespread, relatively even cartilage wear across the hip joint rather than a single focal lesion: the joint environment is degraded, synovial fluid has thinned, and the aim is to restore lubrication and reduce pain across the whole joint surface. A broad age range may benefit, from active middle-aged patients to older individuals managing symptomatic stiffness.

ChondroFiller injection suits focal, full-thickness cartilage damage. The target is a specific, isolated area of cartilage loss — commonly from femoroacetabular impingement (FAI) or previous hip trauma — where the surrounding joint borders remain structurally healthy. MRI is central to candidate selection, confirming the lesion's size, depth, and the integrity of the tissue around it. This regenerative pathway tends to be most relevant in younger, more active patients who have a defined structural problem rather than generalised wear.

Grading guides the boundary. The Mazek (2021) cohort found that patients with Tönnis grade 2–3 osteoarthritis — advanced, diffuse disease — had uniformly poor outcomes with ChondroFiller, making this a clear contraindication. HA evidence is built on mild-to-moderate disease; it is not studied as a treatment for bone-on-bone hip OA.

Patients at the end-stage of hip OA — with severe diffuse joint space loss on imaging — are outside the scope of either injection as a standalone treatment. At that point, hip replacement becomes the appropriate clinical discussion.

What the procedure involves and what the evidence shows

Accurate needle placement is the procedural foundation for both injections. The hip joint sits several centimetres beneath the skin surface, shielded by dense soft tissue, and up to 30% of hip injections placed without image guidance may miss the joint space entirely. Both ChondroFiller and HA hip injections are therefore delivered under real-time ultrasound or fluoroscopic guidance — precision-controlled outpatient procedures carried out under local anaesthesia, with no general anaesthetic or overnight admission required.

Hyaluronic acid: what the evidence shows

HA viscosupplementation for hip OA has been assessed in multiple RCTs and observational studies. Qvistgaard et al (2006) compared HA against corticosteroid and saline in a randomised hip OA trial; Mauro et al (2018) evaluated one, two, and three injection courses in 96 patients with mild-to-moderate hip OA; De Lucia et al (2019) compared high and medium molecular weight HA over repeated courses in a retrospective cohort. Across this evidence base, symptom relief is well documented; structural benefit is limited to indirect stimulation of the joint's own endogenous HA production rather than new tissue formation.

ChondroFiller injection: what the evidence shows

The most specific published hip outcome data for ChondroFiller injection comes from the Mazek (2021) prospective cohort (n=26), which reported MRI-verified cartilage healing in the majority of evaluable patients at three-to-five-year follow-up — findings covered in the preceding section. Larger RCT validation for the injectable hip format remains pending. No published head-to-head trial has compared ChondroFiller injection directly to HA in the hip joint; the available evidence assesses each pathway independently.

Access, cost, and how to find out which pathway fits your hip

Practical access to these two pathways differs considerably.

Hyaluronic acid is widely available across NHS MSK services and private clinics throughout the UK; private costs typically fall in the range of £200–£600 per injection, with some patients receiving courses of two or three injections depending on the formulation chosen.

ChondroFiller injection is not NHS-funded and is not covered by major UK private insurers including Bupa and AXA. Patients access it on a self-funded basis at specialist UK centres, with approximate costs of £2,100–£8,000 per procedure. ChondroFiller is not FDA-approved, which limits its availability outside Europe and the UK.

Cost and access are practical realities, but neither should be the primary basis for pathway selection. MRI-confirmed structural diagnosis — the presence of focal versus diffuse cartilage loss, the grade of osteoarthritis, and the integrity of surrounding joint tissue — is what drives the choice between these two interventions.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment at Sleaford and Grantham, serving patients across Lincolnshire and the wider non-London UK catchment. The right next step for anyone weighing up either pathway is a specialist hip assessment to confirm the structural diagnosis and determine which approach, if either, is appropriate for their joint.